Table 5 Best response with carfilzomib and panobinostat in the overall population
Best response | All | MTD | Bortezomib sensitive | Bortezomib refractory | Prior bortezomib and lenalidomide | Lenalidomide refractory | Bortezomib and lenalidomide refractory |
|---|---|---|---|---|---|---|---|
n = 30 | n = 16 | n = 11 | n = 16 | n = 23 | n = 8 | n = 7 | |
(%) | (%) | (%) | (%) | (%) | (%) | (%) | |
CR | 2 (7) | 1 (6) | 1 (3) | 1 (3) | 2 (9) | – | – |
VGPR | 5 (17) | 3 (19) | 1 (3) | 3 (10) | 2 (9) | 1 (13%) | – |
≥ VGPR | 7 (23) | 4 (25) | 2 (7) | 4 (13) | 4 (17) | 1 (13%) | – |
PR | 10 (33) | 6 (38) | 4 (13) | 5 (17) | 7(30) | 3 (38%) | 3 (43%) |
MR | 4 (13) | 1 (6) | 2 (7) | 2 (7) | 4 (17) | 1 (13%) | 1 (14%) |
SD | 4 (13) | 3 (19) | – | 4 (13) | 4 (7) | 2 (25%) | 2 (29%) |
PD | 5 (17) | 2 (13) | 3 (10) | 1 (3) | 4 (3) | 1 (13%) | 1 (14%) |
ORR | 17 (57) | 10 (63) | 6 (55) | 9 (57) | 11 (48) | 4 (50%) | 3 (43%) |
CBR | 21 (70) | 11 (68) | 8 (73) | 11 (69) | 15 (65) | 5 (63%) | 4 (57%) |
